Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma

医学 阿帕蒂尼 不利影响 内科学 阶段(地层学) 进行性疾病 胃肠病学 栓塞 外科 总体生存率 疾病 生物 古生物学
作者
Guohui Xu,Jun Zhu,Xiaoqian Xu,Yaoyong Chen,Qiang Wang,Quanji Yue,Kaijian Lei,Yuming Jia,Guo Xiao
出处
期刊:Journal of Cancer Research and Therapeutics [BioMed Central]
卷期号:18 (5): 1432-1432 被引量:4
标识
DOI:10.4103/jcrt.jcrt_2401_21
摘要

To evaluation the clinical efficacy and safety of bronchial artery chemoembolization (BACE) combined with apatinib for treatment of advanced central lung squamous cell carcinoma (LSCC).Forty-seven patients with pathologically diagnosed stage IIIB or IV central LSCC that was not resectable were selected among hospital patients presenting after November 2016. Twenty-one patients were treated with BACE combined with apatinib; the remaining patients served as a control group treated with BACE alone. Objective response rate (ORR) and disease control rate (DCR) were evaluated with postoperative contrast-enhanced CT scans at 3, 6, and 12 months. Progression-free survival (PFS) curves were used to evaluate curative effects. Adverse events were recorded to assess safety.BACE operations were successfully completed in all 47 patients. Significant differences were found at six and 12 months (P < 0.05). Median PFS was 322 days in the observation group and 209 days in the control group: a statistically significant difference (P = 0.042). One-year survival rates were 76.19% and 46.15% for observation and control patients, respectively; this difference was also significant (P = 0.037). Three patients in the observation group received emergency interventional embolization for hemoptysis, and patients with grade III or greater adverse reaction events (AE) accounted for 19.05% of patients (4/21); these subjects improved or were controlled after active treatment.BACE combined with apatinib is effective for treatment of advanced central LSCC, with definite short-term efficacy, controllable risk, and high safety. Investigation with a larger sample size is warranted to confirm study results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
卷卷完成签到,获得积分10
刚刚
JSY完成签到 ,获得积分20
刚刚
xyh完成签到,获得积分10
1秒前
小曾应助Florencia采纳,获得10
2秒前
神外王001完成签到 ,获得积分10
2秒前
7秒前
你是谁完成签到,获得积分10
8秒前
majf完成签到,获得积分10
9秒前
linhanwenzhou完成签到,获得积分10
9秒前
JSY关注了科研通微信公众号
9秒前
853225598完成签到,获得积分10
9秒前
798完成签到,获得积分10
10秒前
善学以致用应助董怼怼采纳,获得10
10秒前
妍儿完成签到,获得积分20
11秒前
隐形曼青应助高大的水壶采纳,获得10
11秒前
马哥二弟无敌完成签到 ,获得积分10
12秒前
13秒前
Florencia完成签到,获得积分10
13秒前
务实颜完成签到 ,获得积分10
13秒前
13秒前
amberzyc应助小远采纳,获得10
14秒前
14秒前
15秒前
15秒前
16秒前
16秒前
Rondab应助小猪采纳,获得30
16秒前
DLDL完成签到,获得积分10
16秒前
17秒前
沧海云完成签到 ,获得积分10
17秒前
发嗲的迎天完成签到 ,获得积分10
18秒前
hahaha发布了新的文献求助10
19秒前
小马甲应助zx0914采纳,获得10
19秒前
阳光保温杯完成签到 ,获得积分10
19秒前
微冷潇一应助mo采纳,获得10
20秒前
顺心凝天完成签到,获得积分10
20秒前
yishiqi10086发布了新的文献求助10
21秒前
何相逢应助科研通管家采纳,获得10
22秒前
22秒前
CipherSage应助科研通管家采纳,获得10
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029